GLSI Research and Charts

GLSI - Greenwich LifeSciences Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-26 (Delayed quote data 2025-01-03)

Last 12.88	Change ⇑ +1.14 (+9.71%)	Volume 50,046
	Open 12.02	High 13.42	Low 11.90

8EMA (Daily) 12.01	40EMA (Daily) 12.92	50EMA (Daily) 13.07	STO (Daily) 31.956	MACD Hist (Daily) -0.001
8EMA (Weekly) 12.957	40EMA (Weekly) 13.61	50EMA (Weekly) 13.55	STO (Weekly) 28.866	MACD Hist (Weekly) -0.375


Company Profile
Greenwich LifeSciences Inc is a biopharmaceutical company that is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in most breast cancers at low, intermediate, and high or overexpressor levels.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.